Pyramid Biosciences is developing targeted therapeutics that precisely modulate TRK family cell surface receptors. Its lead oncology candidate, PBI-200, is an orally active, highly brain-penetrant TRK inhibitor designed to overcome acquired resistance mutations seen with current TRK therapies and to treat genomically-defined solid tumors including primary and metastatic brain cancers. PBI-100 is a first-in-class selective TRK modulator with anti-itch, anti-inflammatory and antiproliferative effects being developed for dermatological and inflammatory diseases such as psoriasis and atopic dermatitis. The company intends to advance both programs clinically and expand its scientific development and business strategy. Pyramid is based in Waltham, Mass. The company recently closed $28 million in funding to accelerate these clinical programs.

Total raised

$28M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2020